Aakash Desai: We explored the molecular characteristics of KRAS wildtype PDAC
Aakash Desai, Assistant Professor at O’Neal Comprehensive Cancer Center at UAB, shared on LinkedIn:
“In our latest paper, we explored the molecular characteristics of KRAS wildtype PDAC (Pancreatic Ductal Adenocarcinoma) and found actionable genetic variants.
We conducted an in-depth study of 27 patients with KRASWT PDAC, analyzing genetic variants and transcriptomic profiles. Our findings reveal that KRASWT PDAC is distinct from KRASMUT, with potentially actionable genetic mutations.
One notable case involved a patient with a TFG-MET rearrangement who showed remarkable sensitivity to a multi-tyrosine kinase inhibitor, crizotinib, in vitro. This patient participated in a clinical trial, c-MET inhibitor, and achieved a durable partial response.
Our research underscores the importance of precision oncology, highlighting the potential of RNA-seq and other advanced techniques to identify targetable mutations and tailor treatments to individual tumor characteristics.
Precision medicine’s future is now! Clinical Trials are important options, and should be considered standard of care!!”
Source: Aakash Desai/LinkedIn
Authors: Aakash Desai, Alexander Xiao, Daheui Choi, Merih Toruner, Daniel Walden, Thorvardur Halfdanarson, Steven Alberts, Robert McWilliams, Amit Mahipal, Daniel Ahn, Hani Babiker, Gulnaz Stybayeva, Alexander Revzin, Sani Kizilbash, Alex Adjei, Tanios Bekaii-Saab, Aaron Mansfield, Ryan Carr, and Wen Wee Ma.
